Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740246 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
A Phase 3 study of Anemia, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 594
- Enrollment target
- 1
- Study location
NCT00740246 is a Phase 3 study of Anemia that has completed, run by American Regent. The registered enrollment target is 594 participants, above the 419-participant average among 72 other Anemia trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00740246, a Phase 3 study of Anemia, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 594 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VIT-45
Study Locations (1)
Pennsylvania
- Luitpold Pharmaceuticals - Norristown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 594 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00740246
The ClinicalTrials.gov registry entry for NCT00740246 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 594 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 419-participant average among 72 other Anemia trials with a reported enrollment target (42% higher). The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00740246 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00740246 about?
NCT00740246 is a clinical study titled "Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia". The objective of this study is to evaluate the safety and tolerability of VIT-45 in the treatment of Iron Deficiency Anemia
What is the current status of trial NCT00740246?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 594 participants. The study started on 2005-07. Estimated completion is 2006-05.
What conditions does trial NCT00740246 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT00740246?
The interventions under investigation include: Placebo (DRUG), VIT-45 (DRUG).
Who is sponsoring clinical trial NCT00740246?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00740246 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.